Abstract
A phase II randomized clinical trial was conducted by Taiwan Cooperative Oncology Group (TCOG) to compare the efficacy and safety between the triplet regimen of S-1, leucovorin, oxaliplatin and gemcitabine (SLOG) with the modified FOLFIRNOX (mFOLFIRNOX) as the first-line treatment in locally advanced or metastatic pancreatic ductal Adenocarcinoma (PDAC) patients (TCOG T5217, ClinicalTrials.gov NCT 03443492). The purpose of this study is to assess the cost-effectiveness of SLOG versus mFOLFIRNOX for the group of Metastatic PDAC patients based on the study results from TCOG T5217.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
